Clinical Trials on Liver and Intrahepatic Bile Duct Neoplasm in United Kingdom

Total 1578 results

Fast Forward Pharmaceuticals

Unknown

Pilot Study of FFP104 Dose Escalation in PBC Subjects

Primary Biliary Cirrhosis

Netherlands, United Kingdom
University of Nebraska
National Cancer Institute (NCI)

Completed

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Gastric Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Newcastle-upon-Tyne Hospitals NHS Trust
Newcastle University; National Institute for Health Research, United Kingdom; Department of Health, United Kingdom

Completed

B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis (RITPBC)

Fatigue | Primary Biliary Cirrhosis

United Kingdom
Innovative Digestive Health Education and Research...
NinePoint Medical

Unknown

Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study (VLE-IOV)

Cholangiocarcinoma | Bile Duct Cancer | Primary Sclerosing Cholangitis | Bile Duct Diseases | Pancreatic Ductal Adenocarcinoma | Pancreas Cancer | Bile Duct Neoplasms | Biliary Stricture | Bile Duct Obstruction | Bile Duct Obstruction, Extrahepatic | Pancreatic Duct Stricture | Bile Duct Lesions | Bile Duct Neoplasms... and other conditions

United States
Guy's and St Thomas' NHS Foundation Trust
King's College Hospital NHS Trust

Unknown

Paternally Inherited Phenotypes in Cholestasis (PIP-C)

Primary Sclerosing Cholangitis | Cholestasis | Primary Biliary Cirrhosis

United Kingdom
National Cancer Institute (NCI)

Completed

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Stage IV Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder...

United States
HighTide Biopharma Pty Ltd

Completed

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis (PRONTO-PBC)

Biliary Tract Diseases | Cholangitis | Cholestasis | Primary Biliary Cholangitis | Primary Biliary Cirrhosis | Bile Duct Stricture

United States
University College, London
Eli Lilly and Company

Completed

Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors (ABC-02)

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United Kingdom
University of Alberta
GlaxoSmithKline; Axcan Pharma

Completed

Study of Combivir for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Canada, United Kingdom
Delcath Systems Inc.

Active, not recruiting

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Bile Duct Cancer | Intrahepatic Cholangiocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Bile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic Cholangiocarcinoma

United States
Albireo

Completed

An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects

Primary Biliary Cirrhosis | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis | Orphan Cholestatic Liver Diseases

United Kingdom
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma

Hilar Cholangiocarcinoma | Recurrent Gallbladder Carcinoma | Unresectable Extrahepatic Bile Duct Carcinoma | Unresectable Gallbladder Carcinoma | Gallbladder Adenocarcinoma | Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Bile Duct Adenocarcinoma | Gallbladder Adenocarcinoma With Squamous... and other conditions

United States
Intercept Pharmaceuticals

Terminated

Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, Spain, Canada, United Kingdom, France, Germany, Austria, Netherlands
Emory University
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Effects on Quality of Life With Zinc Supplementation in Patients With Gastrointestinal Cancer

Gastric Carcinoma | Unresectable Pancreatic Carcinoma | Liver and Intrahepatic Bile Duct Carcinoma | Unresectable Esophageal Carcinoma

United States
Mirum Pharmaceuticals, Inc.

Terminated

A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) (OHANA)

Intrahepatic Cholestasis of Pregnancy

United States, United Kingdom, New Zealand
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Pancreatic Cancer | Small Intestine Cancer | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer | Periampullary Adenocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Bayer

Completed

Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas

Pancreatic Cancer | Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Intercept Pharmaceuticals

Completed

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Liver Cirrhosis, Biliary

United States, France, Germany, Spain, United Kingdom, Canada, Austria
University of California, Davis
National Cancer Institute (NCI)

Recruiting

Patient-Derived Xenografts to Reduce Cancer Health Disparities

Gastric Carcinoma | Lung Carcinoma | Malignant Neoplasm | Bladder Carcinoma | Liver and Intrahepatic Bile Duct Carcinoma

United States
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Children's Hospital Medical Center, Cincinnati
Wuhan Union Hospital, China

Not yet recruiting

Intestinal Microbiome Composition in Infants With Biliary Atresia (BA) (BA)

Biliary Atresia | Intrahepatic Cholestases | Normal Controls

United States
Roswell Park Cancer Institute

Completed

Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
National Cancer Institute (NCI)

Completed

A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)

Hepatocellular Carcinoma | Cholangiocarcinoma | Bile Duct Cancer | Biliary Tract Neoplasms | Liver Cancer

United States
Mirum Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)

Primary Biliary Cirrhosis | PBC

United States, United Kingdom, Canada
Leap Therapeutics, Inc.

Completed

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

Cholangiocarcinoma | Bile Duct Cancer | Carcinoma of Intrahepatic and Extra-hepatic Biliary System | Carcinoma of Gallbladder

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus

Cholestasis, Intrahepatic

United Kingdom
CymaBay Therapeutics, Inc.

Recruiting

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Hepatic Impairment | Compensated Cirrhosis | Primary Biliary Cholangitis

Korea, Republic of, United States, Spain, United Kingdom
National Institute of Diabetes and Digestive and...

Completed

Ursodiol-Methotrexate for Primary Biliary Cirrhosis

Liver Cirrhosis, Biliary

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
University of California, Davis

Completed

Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients

Primary Biliary Cirrhosis

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
Imperial College London

Completed

The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus

Gestational Diabetes Mellitus | Intrahepatic Cholestasis of Pregnancy

United Kingdom
Perspectum

Completed

Repeatability and Reproducibility of Quantitative MRCP

Liver Diseases | Primary Sclerosing Cholangitis | Gallstones | Primary Biliary Cirrhosis

United Kingdom
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
The Cleveland Clinic

Completed

Pentoxifylline for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Mayo Clinic

Active, not recruiting

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Mayo Clinic
UCB Pharma

Completed

Moexipril for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Group

Completed

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES PBC)

Primary Biliary Cholangitis

United States
Genfit

Completed

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cholangitis (PBC)

United States, United Kingdom, France, Germany, Spain
University of Florida
Shionogi Inc.; The PBCers Organization

Completed

Use of Fenofibrate for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
University of Miami
Mayo Clinic

Withdrawn

Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Kowa Research Institute, Inc.

Recruiting

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Primary Biliary Cholangitis

United States, Japan
National Cancer Institute (NCI)

Completed

Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery (S1310)

Hilar Cholangiocarcinoma | Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Recurrent Gallbladder Carcinoma | Stage IV Distal Bile Duct Cancer | Unresectable Extrahepatic Bile Duct Carcinoma | Stage II Gallbladder Cancer | Stage... and other conditions

United States
Instituto Ecuatoriano de Enfermedades Digestivas
University of Sao Paulo; Universitair Ziekenhuis Brussel; The Methodist Hospital... and other collaborators

Completed

Artificial Intelligence for Digital Cholangioscopy Neoplasia Diagnosis

Common Bile Duct Neoplasms | Non-Neoplastic Bile Duct Disorder

United States, Ecuador, Belgium, Brazil

Clinical Trials on Liver and Intrahepatic Bile Duct Neoplasm in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations